GSK in breach for misleading prescription information on Omjjara: industry body
Advertisement
London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards in the marketing and prescription information of its drug Omjjara, according to an industry self-regulatory body on Tuesday.
Omjjara is prescribed for the treatment of symptoms such as an enlarged spleen in adults suffering from myelofibrosis - a rare bone marrow blood cancer - and moderate to severe anaemia.
The prescribing information provided for the drug misled women using hormonal contraceptives about the necessity for extra precautions to prevent pregnancy, the Prescription Medicines Code of Practice Authority (PMCPA) said.
According to Reuters, a GSK spokesperson said, "We take adherence to industry codes and regulations very seriously".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.